Constipation related to GLP-1 medications often improves with adequate hydration, gentle movement, and gradual increases in dietary fiber
Addressing the emotional components of eating behavior provides protection during vulnerable transition periods
Many patients notice that eating feels more manageable early on especially compared with options that may take longer to build over time
Many people wonder: When should I increase my GLP-1 dose
Similarly, SGLT2 inhibitors have demonstrated robust cardiovascular and renal benefits, including reductions in cardiovascular events and all-cause mortality, with consistent effects across the drug class and irrespective of diabetes status [6, 7] Their metabolic benefitssuch as weight loss, improved lipid profiles, and reduced visceral adipositycontribute to a favourable cardiovascular risk profile, countering the pro-atherogenic state typical of T2DM [8]
2 THERAPEUTIC INDICATION 1 : Type 2 diabetes mellitus MOUNJARO is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes
.png)
